Browse studies

Find your next paid study

5 recruiting studies matching your filters

A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies

Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and mo…

B-cell MalignancyMarginal Zone LymphomaFollicular Lymphoma+6 more

Estimated

~$10 – $7,500

BeOne MedicinesNCT05006716

Phase 1

A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with tacabrutideg in combination wit…

B-cell MalignancyRelapsed CancerRefractory Cancer+1 more

Estimated

~$10 – $7,500

BeOne MedicinesNCT06634589

Phase 1

A Phase 1b Study of Oral AS-1763 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intol…

B-cell MalignancyChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma+5 more

Estimated

~$10 – $8,750

Carna Biosciences, Inc.NCT05602363

Study of Precursor Hematological Malignancies to Assess the Relationship Between Molecular Events of Progression and Clinical Outcome

Blood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the ca…

Monoclonal Gammopathy of Undetermined Significance (MGUS)Myelodysplastic SyndromesHematological Malignancies+5 more

Estimated

~$10 – $1,125

Dana-Farber Cancer InstituteNCT02269592

Phase 1

A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Subjects With Relapsed or Refractory B Cell Malignancies

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.

B-cell LymphomaNon-Hodgkin LymphomaB-cell Malignancy+5 more

Estimated

~$10 – $8,750

CRISPR Therapeutics AGNCT05643742